Ameriprise
ALLO icon

Ameriprise’s Allogene Therapeutics ALLO Stock Holding History

Ameriprise’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Buy
469,866
+225,274
+92% +$495K ﹤0.01% 3411
2026
Q1 		$597K Buy
+244,592
New +$490K ﹤0.01% 3517
2025
Q2 		– Sell
-244,528
Closed -$357K – 3962
2025
Q1 		$357K Buy
244,528
+42,585
+21% +$80.3K ﹤0.01% 3625
2024
Q4 		$430K Buy
201,943
+24,830
+14% +$61.2K ﹤0.01% 3581
2024
Q3 		$496K Sell
177,113
-160,932
-48% -$429K ﹤0.01% 3476
2024
Q2 		$788K Buy
338,045
+149,005
+79% +$440K ﹤0.01% 3253
2024
Q1 		$845K Sell
189,040
-1,255
-0.7% -$5.24K ﹤0.01% 3234
2023
Q4 		$611K Buy
190,295
+55,704
+41% +$158K ﹤0.01% 3369
2023
Q3 		$427K Buy
134,591
+23,415
+21% +$103K ﹤0.01% 3470
2023
Q2 		$553K Sell
111,176
-697,048
-86% -$3.77M ﹤0.01% 3398
2023
Q1 		$4M Buy
808,224
+167,036
+26% +$1.07M ﹤0.01% 2466
2022
Q4 		$4.03M Sell
641,188
-129,695
-17% -$1.2M ﹤0.01% 2445
2022
Q3 		$8.31M Sell
770,883
-276,682
-26% -$3.76M ﹤0.01% 1831
2022
Q2 		$11.9M Buy
1,047,565
+39,029
+4% +$346K ﹤0.01% 1591
2022
Q1 		$9.19M Buy
1,008,536
+293,874
+41% +$3.06M ﹤0.01% 1975
2021
Q4 		$10.7M Buy
714,662
+332,832
+87% +$5.87M ﹤0.01% 1940
2021
Q3 		$9.81M Buy
381,830
+353,249
+1,236% +$8.39M ﹤0.01% 1873
2021
Q2 		$745K Buy
28,581
+4,234
+17% +$121K ﹤0.01% 3324
2021
Q1 		$859K Sell
24,347
-4,927
-17% -$166K ﹤0.01% 3205
2020
Q4 		$739K Sell
29,274
-1,469
-5% -$47.9K ﹤0.01% 3212
2020
Q3 		$1.16M Sell
30,743
-3,753
-11% -$141K ﹤0.01% 2906
2020
Q2 		$1.48M Buy
+34,496
New +$1.25M ﹤0.01% 2747

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ameriprise's ALLO Position: Q2 2026 in Review

Ameriprise increased its Allogene Therapeutics (ALLO) stake by 92% in Q2 2026, buying an estimated $495K and bringing the position to 469,866 shares worth $977K. The position accounts for ﹤0.01% of the portfolio, ranked #3411.

Ameriprise first reported a position in ALLO in Q2 2020 and has held it in 22 quarters since. The position peaked at $11.9M in Q2 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Ameriprise held 469,866 shares of Allogene Therapeutics worth $977K as of Q2 2026.
  • Ameriprise bought 225,274 Allogene Therapeutics shares in Q2 2026, an estimated $495K.
  • Allogene Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3411 holding.
  • Ameriprise first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • Ameriprise's Allogene Therapeutics position peaked at $11.9M in Q2 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.